Syndax Pharmaceuticals Inc: directors' dealings · United States · SEC (Form 4)

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc. is a United States-listed biopharmaceutical company traded on the NASDAQ under the ticker SNDX. From an international equity perspective, Syndax has evolved from a clinical-stage development story into a more commercial healthcare name, with a focus on oncology and fibrotic disease. The company was founded in 2005, went public in 2016, and is headquartered in Waltham, Massachusetts, in the United States. Its corporate evolution has been shaped by a steady shift from a broader early-stage oncology portfolio toward a smaller set of differentiated, high-value assets. Today, Syndax’s business is centered on two lead medicines. The first is Revuforj® (revumenib), a menin inhibitor designed for hard-to-treat hematologic malignancies, especially acute leukemias with specific genetic alterations. The second is Niktimvo™ (axatilimab-csfr), developed with Incyte, which is used in chronic graft-versus-host disease, a serious complication of stem cell transplantation. These programs place Syndax in attractive therapeutic niches where unmet medical need is high, regulatory differentiation matters, and pricing power can be meaningful if clinical benefit is demonstrated. From a competitive standpoint, Syndax stands out for pursuing scientifically targeted therapies rather than broad franchise diversification. In hematology-oncology, Revuforj has become the company’s core growth driver, supported by strong clinical data and a U.S. FDA approval in 2025, followed by an additional indication later that year. In chronic GVHD, Niktimvo benefits from a partnership model with Incyte that helps share development and commercialization risk while preserving revenue potential. This dual-asset structure reduces reliance on a single program and gives the company a more balanced near-term growth profile. Geographically, Syndax remains primarily focused on the United States, both commercially and operationally, although its clinical and scientific footprint extends internationally through trials and medical congresses. Recent milestones have been particularly important: Revuforj’s commercial launch, FDA approval in October 2025 for relapsed or refractory AML with an NPM1 mutation, and continued uptake of Niktimvo, all of which have helped transition Syndax toward a commercial-stage profile. For investors, the company offers exposure to a specialized U.S. NASDAQ-listed oncology platform with meaningful upside tied to execution, but also the usual biotech risks around launch adoption, label expansion, competition, and regulatory dependence.